We have given our own services a brand and we are facilitating them from Europe to places around the globe. With EMELEMA® we are establishing German vitamin and natural products from Europe in countries outside of Europe. MYROHA® is a platform for the registration and brand building in China. EsoCap® is developing a novel delivery system for the Esophagus.
EMELEMA® - EMELEMA is what drives all our actions. We are convinced the inefficiencies of the global and local health systems refrain patients from getting access to treatments, medicine and diagnostics. EMELEMA® reminds us every day of the purpose we have as Ferro Pharma.
MYROHA® - With our investment into Hangzhou Myroha Biotech Ltd., we have secured our access to China. Myroha Biotech acquired the exclusive rights for Zirkulin® in China in 2016. In 2017, Zirkulin® as a brand got acquired by ProsiebenSat1, a leading German Media company, confirming the exclusive sales rights for Zirkulin® in China to Myroha Biotech. With an extensive network of sales organizations Myroha has started its way to become the leading brand building company for German, Austrian and Swiss brands in the Chinese health sector.
Ferro Pharma was lucky enough to get the chance to participate in a seed round investment of EsoCap®, as one of the most promising and unique drug delivery platforms for the human esophagus. Together with other private investors, we support the development with our know-how and network, in order to prepare the final stages of the development. Please see more information directly on EsoCap’s web site.